X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (554) 554
Publication (39) 39
Book Chapter (1) 1
Book Review (1) 1
Conference Proceeding (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (445) 445
hyperbilirubinemia - chemically induced (371) 371
female (290) 290
male (282) 282
adult (161) 161
animals (148) 148
index medicus (136) 136
middle aged (135) 135
hyperbilirubinemia (124) 124
infant, newborn (113) 113
rats (112) 112
bilirubin - blood (104) 104
aged (81) 81
bilirubin (76) 76
pregnancy (67) 67
pharmacology & pharmacy (58) 58
bilirubin - metabolism (57) 57
pediatrics (57) 57
oncology (51) 51
liver - drug effects (47) 47
adolescent (46) 46
dose-response relationship, drug (44) 44
hiv infections - drug therapy (42) 42
glucuronosyltransferase - genetics (39) 39
liver (38) 38
risk factors (38) 38
time factors (38) 38
treatment outcome (38) 38
jaundice - chemically induced (37) 37
disease models, animal (36) 36
cholestasis - chemically induced (35) 35
liver - pathology (35) 35
hematology (34) 34
atazanavir sulfate (32) 32
hiv protease inhibitors - adverse effects (31) 31
hyperbilirubinemia - blood (31) 31
pyridines - adverse effects (31) 31
chemical and drug induced liver injury - etiology (30) 30
hyperbilirubinemia - complications (30) 30
infant (30) 30
oligopeptides - adverse effects (30) 30
retrospective studies (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
hyperbilirubinemia - genetics (29) 29
liver - metabolism (29) 29
drug administration schedule (28) 28
gastroenterology & hepatology (28) 28
hyperbilirubinemia - etiology (28) 28
care and treatment (27) 27
hyperbilirubinemia - metabolism (27) 27
alanine transaminase - blood (25) 25
anti-hiv agents - adverse effects (25) 25
infectious diseases (25) 25
mice (25) 25
antineoplastic agents - adverse effects (24) 24
genotype (24) 24
hyperbilirubinemia - drug therapy (24) 24
child (23) 23
immunology (23) 23
oligopeptides - therapeutic use (23) 23
prospective studies (23) 23
toxicity (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
child, preschool (22) 22
drug therapy, combination (22) 22
health aspects (22) 22
pyridines - therapeutic use (22) 22
therapy (22) 22
acute disease (21) 21
anti-hiv agents - therapeutic use (21) 21
chemotherapy (21) 21
infants (21) 21
follow-up studies (20) 20
jaundice, neonatal - chemically induced (20) 20
liver function tests (20) 20
medicine, general & internal (20) 20
pharmacokinetics (20) 20
aspartate aminotransferases - blood (19) 19
hepatotoxicity (19) 19
hiv (19) 19
hiv protease inhibitors - therapeutic use (19) 19
hyperbilirubinemia - diagnosis (19) 19
jaundice (19) 19
rats, sprague-dawley (19) 19
safety (19) 19
atazanavir (18) 18
cholestasis (18) 18
liver - enzymology (18) 18
pharmacogenetics (18) 18
polymorphism, genetic (18) 18
rats, gunn (18) 18
rats, wistar (18) 18
research (18) 18
drug interactions (17) 17
glucuronosyltransferase - metabolism (17) 17
hemolysis (17) 17
hyperbilirubinemia - pathology (17) 17
toxicology (17) 17
ugt1a1 (17) 17
alkaline phosphatase - blood (16) 16
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (471) 471
German (25) 25
French (15) 15
Spanish (14) 14
Italian (10) 10
Russian (8) 8
Japanese (7) 7
Polish (3) 3
Dutch (1) 1
Hebrew (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 07/2013, Volume 63, Issue 4, pp. 249 - 279
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for... 
toxicity | kinase inhibitors | therapeutic index | targeted agents | mechanism‐based toxicity | immunotherapeutic agents | off‐target toxicity | mechanism-based toxicity | off-target toxicity | MEK INHIBITOR TRAMETINIB | PULMONARY ARTERIAL-HYPERTENSION | I DOSE-ESCALATION | CHRONIC MYELOID-LEUKEMIA | GROWTH-FACTOR RECEPTOR | ONCOLOGY | PLACEBO-CONTROLLED TRIAL | III CLINICAL-TRIAL | SQUAMOUS-CELL CARCINOMAS | TIVANTINIB ARQ 197 | SIGNAL-REGULATED KINASE | Mood Disorders - chemically induced | Drug Eruptions - etiology | Peripheral Nervous System Diseases - chemically induced | Bone Marrow Diseases - chemically induced | Cachexia - chemically induced | Endocrine System Diseases - chemically induced | Pleural Effusion - chemically induced | Humans | Drug Eruptions - therapy | Immune System Diseases - chemically induced | Lung Diseases, Interstitial - chemically induced | Thrombocytopenia - chemically induced | Diarrhea - chemically induced | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Hyperbilirubinemia - chemically induced | Venous Thromboembolism - chemically induced | Vision Disorders - chemically induced | Hemorrhage - chemically induced | Heart Diseases - chemically induced | Hyperlipidemias - chemically induced | Magnesium - blood | Antimitotic agents | Drugs | Prevention | Complications and side effects | Drug targeting | Antineoplastic agents | Health aspects | Risk factors | Proteins | Side effects | Genomics | Cytotoxicity | Molecular biology | Cancer therapies | Cells | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 5, pp. 573 - 583
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 11, pp. 1979 - 1988
BACKGROUND Advanced cholangiocarcinoma carries a poor prognosis, and no standard treatment exists beyond first‐line gemcitabine/platinum‐based chemotherapy. A... 
vascular endothelial growth factor receptor 2 (VEGFR2) | phase 2 | soluble MET | cholangiocarcinoma | cabozantinib | FACTOR-RECEPTOR | BILIARY-TRACT CANCER | INTRAHEPATIC CHOLANGIOCARCINOMA | INTERLEUKIN-6 | OVEREXPRESSION | ONCOLOGY | C-MET | PROGNOSTIC-SIGNIFICANCE | INHIBITOR | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Proto-Oncogene Proteins c-met - metabolism | Anilides - therapeutic use | Humans | Middle Aged | Placenta Growth Factor - metabolism | Male | Vascular Endothelial Growth Factor A - metabolism | Cholangiocarcinoma - metabolism | Intestinal Perforation - chemically induced | Angiopoietin-2 - metabolism | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Neoplasm Metastasis | Hyperbilirubinemia - chemically induced | Hypertension - chemically induced | Biomarkers, Tumor - metabolism | Female | Neutropenia - chemically induced | Interleukin-6 - metabolism | Bile Duct Neoplasms - drug therapy | Pyridines - therapeutic use | Bile Duct Neoplasms - metabolism | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Epistaxis - chemically induced | Survival Rate | Disease-Free Survival | Cholangiocarcinoma - pathology | Chemokine CXCL12 - metabolism | Cholangiocarcinoma - drug therapy | Protein Kinase Inhibitors - therapeutic use | Intestinal Fistula - chemically induced | Aged | Bile Duct Neoplasms - pathology | Matrix Metalloproteinase 1 - metabolism | Cancer patients | Research | Biological markers | Health aspects | Drugs | Plasma | Gemcitabine | Toxicity | Perforation | Angiopoietin | Interleukin | Population studies | Matrix metalloproteinase | Metastases | Reduction (metal working) | Confidence intervals | Interleukin 6 | Hyperbilirubinemia | Platinum | Intestine | Quality | Metalloproteinase | Inhibition | Vascular endothelial growth factor receptor 2 | Vascular endothelial growth factor | Drug dosages | Cholangiocarcinoma | Age | Neutropenia | Hypertension | SDF-1 protein | Patients | Survival | Chemotherapy | Placenta | Inhibitors | Antiangiogenics | Medical prognosis | Biomarkers | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
The Journal of Pediatrics, ISSN 0022-3476, 07/2003, Volume 143, Issue 1, pp. 16 - 25
Journal Article
Journal Article
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2010, Volume 102, Issue 9, pp. 1371 - 1377
Journal Article